(Q73358382)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9160526%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

title

Development of an adjuvant-active nonionic block copolymer for use in oil-free subunit vaccines formulations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9160526%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

C W Todd

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9160526%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

L A Pozzi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9160526%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

J R Guarnaccia

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9160526%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

M Balasubramanian

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9160526%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

W G Henk

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9160526%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

L E Younger

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9160526%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

M J Newman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9160526%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

language of work or name

English

0 references

publication date

1 April 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9160526%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9160526%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9160526%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9160526%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

564-570

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9160526%20AND%20SRC:MED&resulttype=core&format=json

Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble components

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

In vitro spleen cell responsiveness to various analogs of MDP (N-acetylmuramyl-l-alanyl-d-isoglutamine), a synthetic immunoadjuvant, in MDP high-responder mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

Stimulation of the reticuloendothelial system of mice by muramyl dipeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

A study of the cellular and molecular mediators of the adjuvant action of a nontoxic monophosphoryl lipid A.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

Immunopotentiating effects of the adjuvants SGP and Quil A. I. Antibody responses to T-dependent and T-independent antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

Immunopotentiation by SGP and Quil A. II. Identification of responding cell populations.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

Accessory cell requirements for saponin adjuvant-induced class I MHC antigen-restricted cytotoxic T-lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

Cytokines as immunological adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

Cytokines as vaccine adjuvants: interleukin 1 and its synthetic peptide 163-171.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

Modulation of antiviral immune responses by exogenous cytokines: effects of tumour necrosis factor-alpha, interleukin-1 alpha, interleukin-2 and interferon-gamma on the immunogenicity of an inactivated rabies vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

Recombinant cytokines as immunological adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

Cytokines as potential vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

Stable oil-in-water emulsions: preparation and use as vaccine vehicles for lipophilic adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

Liposomes as immunological adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

Liposomes as immunological adjuvants: antigen incorporation studies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

Biodegradable microspheres as a vaccine delivery system

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

Single-step immunization using a controlled release, biodegradable polymer with sustained adjuvant activity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

The adjuvant activity of nonionic block polymer surfactants. III. Characterization of selected biologically active surfaces

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

The measurement of relative antibody affinity by ELISA using thiocyanate elution

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900209-0

7 January 2021

10.1016/S0264-410X(97)00209-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9160526%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference